6550-- Ventena Contract Request

Special Notice Notice of Intent to Award a Sole Source Procurement The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to Roche Diagnostics Corporation for procurement of the following reagents and consumable supplies: Estimated Annual Quantities Item Description Item Number Quantity 1 Reagent, DAB Detection 760-500 25 2 Reagent, Stainer, Amplification 760-080 20 3 Reagent, Stainer, Reaction Buffer 950-300 40 4 Reagent, Hematoxylin 760-2021 26 5 Reagent, Bluing Agent 760-2037 26 6 Staining Solution, Protease 760-2018 7 7 10x EZ Stainer, Prep Solution, 2L 950-102 15 8 Benchmark Ultra LCS 650-210 80 9 Solution, Ultra, Cell CC1 950-224 14 10 Control, Negative Monoclonal 760-2014 6 11 Elastin Van Gieson Kit 50 Test Cat. 09592229001 6 12 Staining Kit, Complex Stains, Reticulum II 860-024 4 13 Staining Kit, Complex Stains, Special 860-028 4 14 DEPAR Solution, BMK Special Stains 860-036 6 15 Liquid Coverslip, BMK Special Stains 860-034 10 16 Benchmark Special Stains Wash II Catalog 08309817001 8 17 Benchmark Special Stains I Cleaning Kit 860-049 7 18 Ventana H. Pylori (SP48) PAB 790-1014 24 19 CONFIRM ANTI-THRYOID TRANSCRIPTION FACT 790-4398 8 20 Ribbon, Ebar Printer 1632900 3 21 Kit Pack Ebar 1418702 5 22 Confirm Cytokeratin7 Rabbitmono 790-4462 8 23 Antibody KI 67 (30-9) Rabbit Monoclonal 790-4286 8 24 S IHC ANTIBODY ROUTINE: CONFIRM ANTI-S100 (POLYCLONAL) PAB 760-2523 6 25 CONFIRM CYTOKERATIN 20 RABBIT MONO 790-4554 10 26 CONFIRM CYTOKERATIN 20 RABBIT MONO 790-4431 6 27 ANTI-CHROMOGRANIN A (LK2H10) PAB 760-2519 4 28 CONFIRM CYTOKERATIN 20 RABBIT MONO 790-7061 4 29 CD-138 (B-A38) PAB, CELL MARQUE 790-4248 4 30 CONFIRM ANTI-CD34 (QBEND/10) PRIMARY ANTIBODY 790-2927 4 31 CONFIRM ANTI-CD3 (2GV6) RABBIT MONOCLONAL 790-4341 4 32 CONFIRM ANTI-CD5 (SP19) RABBIT MONO 790-4451 4 33 CONFIRM ANTI-CD20 (L26) PAB 760-2531 4 34 CD68 (SP251V18) RABBIT MONOCLONAL AB 790-7248 4 35 VENTANA ANTI-CD10 (SP67) 790-4506 4 36 CONFIRM ANTI-SYNAPTOPHYSIN (SP11) RABBIT 790-4407 4 37 CYTOKERATIN (CAM 5.2) PAB 790-4555 4 38 IHC ANCILLARY, HEMATOXYLIN II 790-2208 2 39 IHC ANCILLARIES, OPTIVIEW AMPLIFICATION KIT 760-099 2 40 IHC ANCILLARIES: OPTIVIEW DAB DETECTION KIT (250) 760-700 2 The requested items will be used on the Ventana BenchMark Ultra system. The requesting activity states that the government owns and operates a Ventana BenchMark Ultra System and that the requested reagents and consumable supplies are the only supplies compatible with the instrument. A sole source letter from Roche states that all Ventana detection reagents, ancillaries, antibodies and probes are developed and validated for exclusive use on the fully automated Ventana Benchmark IHC/ISH slide staining system and cannot be substituted. The proposed order will be considered a standing order; where, the supplies will be ordered throughout the period of performance, on an as-needed basis. Network Contracting Office 17 will request the acquisition of these supplies from Roche on an IDIQ contract with a five-year ordering period. This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice; however, all responsible sources may submit a capability statement, proposal or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 5 days from the publication of this notice, a contract/order will be issued to Roche Diagnostics Corporation without any further notice. The proposed contract actions are for supplies, which the government intends to negotiate with only one source. The anticipated statutory authorities permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The proposed sole source procurement will be made by an open market pricing agreement with Roche Diagnostics Corporation.